US Patent 7846908 RNAi modulation of TGF-beta and therapeutic uses thereof
Patent 7846908 was granted and assigned to Alnylam Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+361 characters)
Article
Patent abstract
The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Hans-Peter Vornlocher0
Pamela Tan0
Rainer Constien0
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07846908 RNAi modulation of TGF-beta and therapeutic uses thereof US Patent 7846908 RNAi modulation of TGF-beta and therapeutic uses thereof
Infobox
Patent Number
078469080
Patent Number
78469080
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078469080
Date of Patent
December 7, 2010
0Patent Application Number
117247900
Date Filed
March 15, 2007
0Official Website
Patent Primary Examiner
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07846908 RNAi modulation of TGF-beta and therapeutic uses thereof
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07846908
Date of patent
December 7, 2010
Patent application number
11724790
Date Filed
March 15, 2007
Patent primary examiner
Find more entities like US Patent 7846908 RNAi modulation of TGF-beta and therapeutic uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.